Functionalized triazines as potent HCV entry inhibitors.

Autor: Mull ES; Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: eric_mull@hotmail.com., Sun LQ; Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Zhao Q; Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Eggers B; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Pokornowski K; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Zhai G; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Rajamani R; Department of Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Jenkins S; Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Kramer M; Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Wang YK; Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Fang H; Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Tenney D; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Baldick CJ; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Cockett MI; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Meanwell NA; Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States., Scola PM; Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, United States.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2017 Feb 15; Vol. 27 (4), pp. 1089-1093. Date of Electronic Publication: 2016 Dec 18.

Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies.

Autor: Ghorayshian, Atefeh¹ (AUTHOR), Danesh, Mahshid² (AUTHOR), Mostashari-Rad, Tahereh³ (AUTHOR) t.mostashari@pharm.mui.ac.ir, fassihi, Afshin⁴ (AUTHOR) t.mostashari@pharm.mui.ac.ir

Publikováno v: PLoS ONE. 8/24/2023, Vol. 18 Issue 8, p1-24. 24p.

A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape.

Autor: Lehmann, Felix¹ (AUTHOR) felix.lehmann@viro.med.uni-giessen.de, Slanina, Heiko¹ (AUTHOR) heiko.slanina@viro.med.uni-giessen.de, Roderfeld, Martin² (AUTHOR) martin.roderfeld@innere.med.uni-giessen.de, Roeb, Elke² (AUTHOR) elke.roeb@innere.med.uni-giessen.de, Trebicka, Jonel³ (AUTHOR) jonel.trebicka@ukmuenster.de, Ziebuhr, John¹ (AUTHOR) john.ziebuhr@viro.med.uni-giessen.de, Gerlich, Wolfram H.¹ (AUTHOR) wolfram.h.gerlich@viro.med.uni-giessen.de, Schüttler, Christian G.¹ (AUTHOR) christian.schuettler@viro.med.uni-giessen.de, Schlevogt, Bernhard^3,4 (AUTHOR) bernhard.schlevogt@klinikum-os.de, Glebe, Dieter¹ (AUTHOR) dieter.glebe@viro.med.uni-giessen.de

Publikováno v: Viruses (1999-4915). Apr2023, Vol. 15 Issue 4, p838. 16p.

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.

Autor: Colonno RJ; Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA. richard.colonno@bms.com, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2006 Dec; Vol. 44 (6), pp. 1656-65.

Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.

Autor: Zhenyun Yang, Renguo Guan, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang

Publikováno v: Frontiers in Cellular & Infection Microbiology; 2024, p1-12, 12p